Skip to main content
. 2012 Sep 18;107(11):1714–1724. doi: 10.1038/ajg.2012.255

Table 1. Summary of patient demographic and baseline characteristics (ITT population).

  Placebo, N=395 Linaclotide 290 μg, N=405
Demographic data
 Age (years), mean (range) 43.7 (18–84) 43.3 (19–81)
  ≥65 years, n (%) 26 (6.6) 19 (4.7)
 Sex, n (%)
  Female 357 (90.4) 367 (90.6)
  Male 38 (9.6) 38 (9.4)
 Race, n (%)
  White 301 (76.2) 314 (77.5)
  Black 75 (19.0) 78 (19.3)
  Other 19 (4.8) 13 (3.2)
 BMI, mean (s.d.) 27.6 (6.2) 28.3 (6.4)
Abdominal symptoms, mean (s.d.)
 Abdominal paina 5.6 (1.7) 5.7 (1.7)
 Abdominal discomforta 6.0 (1.7) 6.2 (1.6)
 Abdominal bloatinga 6.5 (1.9) 6.7 (1.8)
 Abdominal fullnessa 6.5 (1.8) 6.8 (1.7)
 Abdominal crampinga 5.4 (1.9) 5.4 (1.9)
Bowel symptoms, mean (s.d.)
 CSBMs/week 0.2 (0.5) 0.2 (0.5)
 SBMs/week 1.9 (1.4) 1.9 (1.4)
 Stool consistencyb 2.4 (1.0) 2.3 (1.0)
 Strainingc 3.4 (0.8) 3.6 (0.8)
Constipation severityd 3.7 (0.6) 3.8 (0.6)
IBS severityd 3.7 (0.6) 3.7 (0.6)

BMI, body mass index; CSBM, complete SBM; IBS, irritable bowel syndrome; ITT, intent-to-treat; SBM, spontaneous bowel movement.

a

Assessed using an 11-point Numerical Rating Scale: 0=none; 10=very severe.

b

Assessed using the BSFS: 1=separate hard lumps, like nuts (hard to pass); 2=sausage-shaped, but lumpy; 3=like a sausage but with cracks on its surface; 4=like a sausage or snake, smooth and soft; 5=soft blobs with clear cut edges (passed easily); 6=fluffy pieces with ragged edges, a mushy stool; 7=watery, no solid pieces (entirely liquid).

c

Assessed using a 5-point ordinal scale: 1=not at all; 2=a little bit; 3=a moderate amount; 4=a great deal; 5=an extreme amount.

d

Assessed using a 5-point ordinal scale: 1=none; 2=mild; 3=moderate; 4=severe; 5=very severe.

All demographic characteristics were similar between treatment groups. For baseline clinical characteristics, significant differences were observed for abdominal fullness (P=0.011), stool consistency (P=0.046), and straining (P=0.020).